A multicenter, open-label, randomised, two-treatment, twoÂsequence, cross-over, steady-state clinical bioequivalence study of Felbamate 600mg tablet of Lannett Company Inc., USA with FelbatolÂ® 600mg tablet of Meda Pharmaceutical Inc., USA in adult epileptic (partial seizures with and without generalization) patients already established (run-in) on Felbamate as an adjunctive therapy under fasting state.

annett Company Inc0 个研究点目标入组 38 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 尚未招募
发起方
入组人数: 38

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•The patients who fulfill all the following inclusion criteria will be included:
•i.Patients should be in the range of 18 - 45 years of age (both inclusive).
•ii.BMI should be in the range of 18.5 to 24.9 Kg/m2 for male volunteers and 18.0 to 27.9 Kg/m2 for female volunteerâ??s (both inclusive).
•iii.Patients having refractory partial seizures with and without generalization not controlled on standard antiepileptic drugs at therapeutic levels
•iv.Patients with normal findings as determined by baseline history, physical examination and vital signs (blood pressure, pulse rate, respiratory rate and axillary temperature).
•v.Patients with normal/ not significant laboratory values as determined by hematological tests, biochemistry, urine analysis and ECG in correlation with clinical findings.
•vi.Willingness to follow the protocol requirement as evidenced by written informed consent.
•vii.Agreeing to, not using or conforming to not having used any medication (prescription and over the counter), including vitamins and minerals for 15 days prior to study & during the course of the study.
•viii.No history or presence of significant alcoholism.
•ix.No history of drug abuse.
•x.Non-smokers, ex-smokers and moderate smokers will be included. â??Moderate smokersâ?? are defined as those who smoke 10 cigarettes or less per day, â??Ex-smokersâ?? are those who stopped smoking for at least 3 months.
•xi.All female patients having negative serum pregnancy test prior to enrolling into the study. All female patients who are of child bearing potential or those within the first two years of the onset of menopausal syndrome using acceptable methods of birth control at least 30 days prior to onset of screening period and till 30 days post last dose of study drug in period-II. Acceptable birth control methods include Barrier methods such as diaphragm/condom with spermicide. Unacceptable methods include oral or implanted contraceptives.

排除标准

•The patients meeting with any one of the following criteria should be excluded:
•i.History of aplastic anemia or hepatic failure
•ii.Requiring medication for any ailment having enzyme-modifying activity in previous one month, prior to drug administration day other than Felbamate
•iii.History of cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological (other than refractory epilepsy), metabolic hematological, gastrointestinal, endocrine or immunological.
•iv.At baseline (Prior to randomization):
•ï?§Two-fold increase in the highest, 2-day pre-study seizure frequency
•ï?§Single generalized, tonic-clonic seizure if none occurred during pre-treatment screening and/or
•ï?§Significant prolongation of generalized, tonic-clonic seizures and Status Epilepticus.
•v.Participation in any other clinical study within 90 days prior to onset of screening period.
•vi.History of malignancy or any other serious diseases.
•vii.Any contraindication to blood sampling.
•viii.Refusal to abstain from smoking or consumption of tobacco products 72.00 hours before morning drug administration on days- 10 and 20 and until after the last blood sample collection in each study period.
•ix.Use of xanthine containing food or beverages (chocolates, tea, coffee or cola drinks), grapefruit juice or products containing grapefruit and alcohol and any alcoholic products, for 72.00 hours before morning drug administration on days- 10 and 20 and until after the last blood sample collection in each study period.
•x.Blood donation within 90 days prior to the commencement of the study.
•xi.Patients with positive HIV I and II tests, HBsAg or HCV tests.
•xii.Positive urine screen for drugs of abuse and breath alcohol test done during check-in process.
•xiii.Positive urine pregnancy test and serum pregnancy test for female patients done during screening and check-in process, respectively.
•xiv.A history of allergic or adverse reactions to Felbamate or any comparable or similar product.
•xv.A history of severe hepatic impairment, drug induced leukopenia/neutropenia, congenital prolongation of the QT interval, cardiac arrhythmias, myocardial infarction or unstable heart disease

研究者

发起方

annett Company Inc

相似试验

已完成

不适用

A Clinical Trial to study the clinical bioequivalence of Clozapine 100 mg tablet of Aurobindo in comparison to ClozarilÂ® (Clozapine) 100 mg tablet of Novartis in patients suffering from Schizophrenia

CTRI/2013/06/003745Aurobindo Pharma Limited36

招募中

不适用

To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations

CTRI/2012/08/002940Hetero Labs Ltd64

已完成

不适用

To assess the safety and tolerability of a single oral dose of the Capecitabine test and reference formulations.

CTRI/2012/07/002778Hetero Labs Ltd64

已完成

不适用

A comparative study of Doxorubicin Hydrochloride in ovarian and/or breast cancer patients.

CTRI/2017/07/009118Dr Reddys Laboratories Ltd85

已完成

不适用

Bioequivalence study ofDoxorubicin Hydrochloride (Pegylated liposomal concentrate for solution for infusion 20 mg/10mL (2 mg/ml) in advanced ovarian cancer.

CTRI/2015/10/006241Dr Reddys Laboratories Limited65